desc,gpt4
epilepsy,1.0
partial epilepsy,1.0
"epilepsy, recurrent seizures, convulsions",1.0
generalized convulsive epilepsy,1.0
electroencephalogram (eeg),1.0
levetiracetam,1.0
convulsions,0.85
lamotrigine,1.0
lacosamide,1.0
clobazam,0.85
zonisamide,1.0
topiramate,0.9
10-hydroxycarbazepine,0.9
valproate,1.0
phenytoin,1.0
phenobarbital,0.85
valproic acid,1.0
phenytoin free,0.85
norclobazam,0.85
rufinamide,1.0
ethosuximide,1.0
"lack of normal physiological development, unspecified",0.1
fosphenytoin,1.0
other conditions of brain,0.5
carbamazepine,1.0
"encephalopathy, not elsewhere classified",0.25
develomental delays and disorders,0.25
felbamate,1.0
primidone,1.0
eslicarbazepine,1.0
oxcarbazepine,1.0
mental retardation,0.1
carnitine free (c0),0.05
interpretation (carnitinep) (group:icar),0.05
"encephalitis, non-infectious",0.25
levocarnitine,0.1
carnitine,0.1
acylcarnitine,0.05
"other conditions of brain, nos",0.25
citric acid / potassium citrate,0.05
encephalitis,0.25
neuromuscular disorder panel (group:nmd),0.1
neurological disorders,0.5
lactate,0.05
ammonia,0.05
nmda nr1 ab (group:nmda-nr1),0.1
lack of normal physiological development,0.1
other specified nonpsychotic and/or transient mental disorders,0.2
gabapentin,0.85
gamma aminobutyrate,0.25
autism,0.05
acylcarnitine/carnitine.free (c0),0.05
nonspecific abnormal results of function study of brain and central nervous system,0.65
abnormal findings on study of brain and/or nervous system,0.65
aphasia/speech disturbance,0.25
transient alteration of awareness,0.85
aphasia,0.1
infantile cerebral palsy,0.1
myoclonus,0.75
argininosuccinate,0.05
valproate free,0.75
aspartate,0.0
hydroxyproline,0.05
citrulline,0.01
ampa-receptor ab (group:ampa-r),0.2
cystine,0.05
cv2 ab,0.0
nervous system congenital anomalies,0.3
cerebral edema and compression of brain,0.2
glycine,0.1
diazepam,0.75
amino acids,0.05
beta hydroxybutyrate,0.05
alloisoleucine,0.0
carnitine.free (c0)/carnitine.total,0.1
homocitrulline,0.05
carnitine esters,0.1
alteration of consciousness,0.65
voltage-gated potassium channel ab,0.65
ethanolamine,0.0
lysine,0.01
arginine,0.0
asparagine,0.0
histidine,0.0
glutamate,0.2
leucine,0.0
isoleucine,0.0
glutamine,0.05
3-methylhistidine,0.01
"amino acids, ser/plas (group:paap)",0.05
altered mental status,0.65
poisoning by anticonvulsants and anti-parkinsonism drugs,0.75
mild cognitive impairment,0.2
cancer of brain,0.1
malignant and unknown neoplasms of brain and nervous system,0.1
cancer of brain and nervous system,0.1
"benign neoplasm of brain, cranial nerves, meninges",0.2
intracerebral hemorrhage,0.1
"cerebral artery occlusion, with cerebral infarction",0.1
occlusion of cerebral arteries,0.1
intracranial hemorrhage (injury),0.1
benign neoplasm of brain and other parts of nervous system,0.25
skull and face fracture and other intercranial injury,0.1
intracranial hemorrhage,0.1
computerized axial tomography (ct) scan head,0.25
"persons with potential health hazards related to socioeconomic, psychosocial, and other circumstances",0.05
delirium due to conditions classified elsewhere,0.1
hemiplegia,0.1
other cerebral degenerations,0.25
total phenytoin concentration,0.85
cerebral ischemia,0.1
essential tremor,0.1
other tests,0.1
acquired hypothyroidism,0.05
late effects of cerebrovascular disease,0.1
fetal distress and abnormal forces of labor,0.0
coma,0.2
hydrocephalus,0.2
hypothermia/chills,0.0
toxic effect of (non-ethyl) alcohol and petroleum and other solvents,0.05
transient cerebral ischemia,0.1
incision and excision of cns,0.3
cerebral cysts,0.2
delirium dementia and amnestic and other cognitive disorders,0.1
dementias,0.1
cerebral aneurysm,0.1
other signs and symptoms involving emotional state,0.2
congenital anomalies of peripheral vascular system,0.0
cerebrovascular disease,0.1
subdural hemorrhage,0.1
hypertensive heart disease,0.0
temozolomide,0.1
total dilantin concentration,0.85
extrapyramidal disease and abnormal movement disorders,0.2
other open wound of head and face,0.1
valproic acid serum concentration,0.85
abnormal involuntary movements,0.25
vascular dementia,0.05
migrain with aura,0.1
phenytoin (dilantin) concentration,0.85
visual field defects,0.1
other headache syndromes,0.1
migraine,0.1
symptoms involving nervous and musculoskeletal systems,0.25
simplythick,0.0
subarachnoid hemorrhage,0.05
phenytoin concentration,0.85
lack of coordination,0.25
other hypertensive complications,0.05
other and unspecified disorders of the nervous system,0.25
melatonin,0.1
phenytoin (dilantin) serum concentration,0.85
somatoform disorder,0.05
syncope and collapse,0.25
nystagmus and other irregular eye movements,0.25
constipation,0.0
vitamin d deficiency,0.05
pentobarbital_drip_50_ml_(mk),0.1
pentobarbital_drip_500_ml_(mk),0.1
valproate_1000mg_+_ns_50ml_kit,0.85
phenytoin.bound,0.85
echovirus antibody type 7,0.05
western equine encephalitis immunoglobulin m,0.05
influenza virus type b antibody,0.0
echovirus antibody type 9,0.05
western equine encephalitis immunoglobulin g,0.05
echovirus antibody type 11,0.05
eastern equine encephalitis immunoglobulin m,0.05
influenza virus type a antibody,0.0
echovirus antibody type 4,0.05
echovirus antibody type 30,0.05
"underdosing of other antiepileptic and sedative-hypnotic drugs, initial encounter",1.0
pentobarbitaldrip2500mg(mk)maxconc,0.1
zinc_gluconate_(60mg_element_zinc),0.05
eastern equine encephalitis virus ab,0.05
methohexital_sodium_1%_10_ml_syringe,0.1
pentobarbital,0.1
amniotic bilirubin scan,0.0
cbc/diff/plt infant(magee),0.0
delta absolute extracted scan,0.1
standard liley value,0.0
amniotic bilirubin interpretation,0.0
delta absolute 450 direct scan,0.05
perampanel,1.0
free phenytoin/dilantin pkg      ,0.85
"underdosing of hydantoin derivatives, initial encounter",0.85
thyroxine binding globulin,0.05
toxoplasma gondii igg,0.05
levetiracetam (keppra),1.0
valproate_sodium_400_mg/8_ml_syrup,0.85
ezogabine,1.0
genital culture w/anaerobes(magee),0.0
cytogenetic report (gastrointestinal stromal),0.0
valproatesodium125mg/2.5mlsyrup,0.85
diagnostic amniocentesis,0.0
levocarnitine1gm/10mloralsoln,0.05
"carbamazepine 10,11-epoxide",0.85
ketamine1250mg/ns250ml(scan-donotuse),0.05
bound valproic acid/depakene level,0.85
percentage bound valproic acid/ depakene level,0.85
"toxoplasma gondii dna, ql, pcr",0.05
phenobarbitaldrip50ml(mk),0.85
other magnesium (magnesium),0.1
x-phenytoin_1000mg+_ns_250ml_kit,0.85
sertraline,0.1
varicella zoster virus dna,0.05
phenytoin_oral_susp_250_mg/10_ml,0.85
rickettsia typhus group igg,0.0
rickettsia spotted fever group igg,0.0
rickettsia spotted fever group igm,0.0
rickettsia typhus group igm,0.0
typhus fever group immunoglobulin g/immunoglobulin m interpretation,0.0
rickettsia antibody panel interpretation,0.0
midazolam100mg/ns100mlpmx(cabinetuseonly),0.25
lacosamidedrip100mg(mk),0.85
carbamazepine free,0.85
herpes simplex virus 1 igm,0.0
oxcarbazepine (trileptal),1.0
lacosamidedrip300mg(mk),0.85
screening for other eye conditions,0.0
cytomegalovirus dna,0.05
baclofen,0.1
brivaracetam,1.0
parietal cell antibody,0.01
other specified congenital anomalies of nervous system,0.25
barbiturates,0.25
divalproex sodium,1.0
Purine and Pyrimidine panel,0.1
clonazepam,0.85
Rufinamide,1.0
everolimus,0.2
OXcarbazepine,0.9
pyruvate,0.05
octenoylcarnitine (c8:1),0.05
3-hydroxydodecanoylcarnitine (c12-oh),0.1
octanoylcarnitine (c8),0.1
linoleoylcarnitine (c18:2),0.05
tetradecenoylcarnitine (c14:1),0.05
3-Hydroxyisovalerylcarnitine (C5-OH),0.1
oleoylcarnitine (c18:1),0.05
butyrylcarnitine (c4),0.05
hexanoylcarnitine (c6),0.1
3-hydroxytetradecanoylcarnitine (c14-oh),0.1
stearoylcarnitine (c18),0.05
dodecanoylcarnitine (c12),0.05
decanoylcarnitine (c10),0.05
decenoylcarnitine (c10:1),0.05
propionylcarnitine (c3),0.1
isovalerylcarnitine+methylbutyrylcarnitine (c5),0.1
Isovalerylcarnitine (C5),0.1
tetradecanoylcarnitine (c14),0.1
tetradecadienoylcarnitine (c14:2),0.05
acylcarnitine pattern,0.1
glutarylcarnitine (c5-dc),0.1
acetylcarnitine (c2),0.1
dodecenoylcarnitine (c12:1),0.05
other paralytic syndromes,0.2
other persistent mental disorders due to conditions classified elsewhere,0.2
blindness and low vision,0.05
valine,0.0
clorazepate,0.85
Chromosome analysis copy number change panel,0.1
methionine,0.01
taurine,0.1
threonine,0.0
serine,0.0
alanine,0.0
proline,0.0
ornithine,0.05
amino acid pattern,0.05
phenylalanine,0.05
tyrosine,0.0
tryptophan,0.05
Bromide,0.75
delayed milestones,0.2
"symptoms concerning nutrition, metabolism, and development",0.1
sleep apnea,0.1
benign neoplasm of kidney and other urinary organs,0.0
other ill-defined and unknown causes of morbidity and mortality,0.1
bipolar,0.0
glaucoma,0.0
sleep related movement disorders,0.2
posttraumatic stress disorder,0.05
other mental disorder,0.2
cataract,0.0
schizophrenia,0.0
attention deficit hyperactivity disorder,0.05
diabetic retinopathy,0.0
visual disturbances,0.5
respiratory failure,0.05
adrenal hypofunction,0.05
kyphoscoliosis and scoliosis,0.0
adjustment reaction,0.05
mood disorders,0.1
other nutritional deficiency,0.1
abnormality of gait,0.2
dependence on respirator [ventilator] or supplemental oxygen,0.05
sleep disorders,0.25
vitamin b-complex deficiencies,0.1
electrolyte imbalance,0.25
other symptoms,0.1
"paroxysmal tachycardia, unspecified",0.05
e. coli,0.0
chronic pulmonary heart disease,0.0
protein-calorie malnutrition,0.05
atrioventricular [av] block,0.05
other specified cardiac dysrhythmias,0.05
pneumonitis due to inhalation of food or vomitus,0.0
hypertensive heart and/or renal disease,0.0
insomnia,0.1
hypoglycemia,0.1
type 1 diabetes,0.0
subjective visual disturbances,0.25
urinary incontinence,0.05
senile cataract,0.0
acid-base balance disorder,0.1
alcoholism,0.05
alcohol-related disorders,0.1
disturbance of skin sensation,0.1
acute pulmonary heart disease,0.0
premature beats,0.1
hearing loss,0.05
open-angle glaucoma,0.0
other disorders of metabolism,0.1
acute renal failure,0.0
occlusion and stenosis of precerebral arteries,0.1
disorders of calcium/phosphorus metabolism,0.1
spinal stenosis of lumbar region,0.05
bacterial pneumonia,0.0
strabismus (not specified as paralytic),0.05
"uveitis, noninfectious or nos",0.0
cough,0.0
asphyxia and hypoxemia,0.1
astigmatism,0.0
"chronic kidney disease, stage i or ii",0.0
chronic pain syndrome,0.1
hyperlipidemia,0.05
facial weakness,0.1
torsion dystonia,0.1
spinal disorders and injuries without cc/mcc,0.05
seizures without mcc,0.85
vimpat,1.0
levetiracetam 500 mg oral tablet,0.9
dilantin,1.0
zonisamide 100 mg oral capsule,0.9
onfi,1.0
keppra,1.0
5 ml levetiracetam 100 mg/ml injection,1.0
phenytoin sodium 100 mg extended release oral capsule,1.0
levetiracetam 250 mg oral tablet,0.9
tricyclic antidepressant screen,0.1
salicylate,0.05
acetaminophen,0.0
lamictal,1.0
barbiturate screen,0.1
benzodiazepine screen,0.25
2 ml phenytoin sodium 50 mg/ml injection,1.0
trileptal,0.9
lamotrigine 100 mg oral tablet,0.9
cipro,0.0
seizure pads,0.85
stx1,0.0
utx2,0.0
stx3,0.0
ethanol,0.05
levetiracetam 100 mg/ml oral solution,1.0
seizure duration,0.85
1 ml lorazepam 2 mg/ml cartridge,0.25
stx5,0.0
stx4,0.0
eeg,0.85
"barbiturate screen, urine",0.1
"benzodiazepine screen, urine",0.25
5 ml valproic acid 100 mg/ml injection,0.85
"amphetamine screen, urine",0.05
"methadone, urine",0.05
"cocaine, urine",0.05
"opiate screen, urine",0.05
oxycodone,0.05
valproic acid 50 mg/ml oral solution,0.85
long-term (current) use of other medications,0.25
stx6,0.0
cerebyx,0.9
utx1,0.0
utx5,0.0
utx7,0.0
utx4,0.0
utx6,0.0
utx3,0.0
seizure activity,0.85
24 hr divalproex sodium 500 mg extended release oral tablet,0.85
"treatment, fracture or dislocation of hip and femur",0.0
multiple sclerosis and cerebellar ataxia with mcc,0.05
diagnostic spinal tap,0.1
depacon,0.85
stx2,0.0
"phenytoin sodium, prompt, 50 mg/ml injectable solution",1.0
oxcarbazepine 150 mg oral tablet,0.85
uro-mag,0.0
depakene,0.9
100 ml sodium chloride 9 mg/ml injection,0.01
amorphous crystals,0.0
divalproex sodium 500 mg delayed release oral tablet,0.85
divalproex sodium 250 mg delayed release oral tablet,0.85
lamotrigine 25 mg oral tablet,0.9
cannula sites visually inspected (ecmo),0.0
malaise and fatigue,0.1
0.4 ml enoxaparin sodium 100 mg/ml prefilled syringe,0.0
effects of other external causes,0.1
topamax,0.9
psychosis,0.1
phenobarbital 130 mg/ml injectable solution,0.85
lorazepam 1 mg oral tablet,0.25
urinary tract infection,0.0
"alcohol, drug abuse or dependence without rehabilitation therapy without mcc",0.05
magnetic resonance imaging,0.25
blue top hold,0.0
antiepileptic drug resistance,1.0
"cenobamate - ontozry, 200 mg tablet",1.0
"sodium phenytoin - diphantoin, 100mg quadri-scored tablet",1.0
"continuous electroencephalographic monitoring with video recording, per 24 hours",1.0
"vigabatrin - kigabeq, 500 mg dispersible tablet",1.0
"long-term electroencephalography of more than 4 hours on 8 channels or more, with video recording",1.0
ambulatory continuous electroencephalography with 8 or more leads for at least 24 hours [holter eeg],1.0
ketocal unflavored box 300g,0.2
"zonisamide, 50 mg capsule",0.9
"brivaracetam - briviact, 75 mg tablet",1.0
"profound intellectual disability, other behavioral impairments",0.1
"implantation of a vagus nerve stimulator, by direct approach",0.85
"zonisamide, 25 mg capsule",0.9
cloBAZam and norclobazam panel,0.85
"change of a vagus nerve stimulation generator, by direct approach",0.85
"profound intellectual disability, significant behavioral impairment, requiring supervision or treatment",0.1
"electroencephalography on 14 or more leads with a minimum recording duration of 20 minutes, with digitization in a patient aged 6 years or older",0.85
"brivaracetam - briviact, 25 mg tablet",1.0
"nitrazepam - mogadon, 5 mg scored tablet",0.75
"cannabidiol - epidyolex, 100 mg/ml oral sol 100 ml bottle",1.0
"levetiracetam, 100 mg/ml oral soln bottle 300 ml + syr 10 ml",1.0
stiripentol,1.0
"zonisamide, 100 mg capsule",0.9
vigabatrin,1.0
"brivaracetam - briviact, 100 mg tablet",1.0
"cerliponase alfa 300 mg (brineura), solution for infusion, 2 vials & vial, 10 ml",0.0
"vigabatrin - kigabeq, 100 mg dispersible tablet",1.0
"midazolam - buccolam, 7.5 mg oral sol spray 1.5 ml",0.75
"removal of a vagus nerve stimulation generator, by direct approach",0.85
"brivaracetam - briviact, 50 mg tablet",1.0
"cannabidiol - epidyolex, 100 mg/ml oral solution",1.0
antiepileptic drugs,1.0
"long-term electroencephalography of 1 to 4 hours on 8 channels or more, with video recording",0.85
"mild intellectual disability, other behavioral impairments",0.2
melatonin 3mg capsule,0.1
"midazolam - buccolam, 10 mg oral solution buccal spray 2 ml",0.75
electroencephalography on 8 leads or more with a minimum recording duration of 20 minutes without digitization and without video recording,0.85
"electroencephalography on 8 channels or more with a minimum recording duration of 30 minutes, with digitization and video recording, in a patient under 6 years old.",0.85
"ospolot 50 mg, tablets",0.75
dosage,0.0
clobazam + nor pnl serpl,0.85
mixed specific developmental disorders,0.1
"mental retardation, unspecified, with significant behavioral impairment, requiring supervision or treatment",0.1
brain perfusion spect without activation test,0.25
"severe mental retardation, significant behavioral impairment, requiring monitoring or treatment",0.1
excision of an epileptogenic zone by craniotomy,1.0
psychogenic disorder,0.2
"severe mental retardation, other behavioral impairments",0.1
"levetiracetam, 100 mg/ml oral soln bottle 150 ml + syr 3 ml",1.0
specific nonpsychotic mental disorders due to brain damage,0.3
"cerestab 500 ug, kit for radiopharmaceutical preparation",0.0
"magnetic resonance imaging (mri) of the skull and its contents, without intravenous contrast agent injection",0.65
critical period cerebral perfusion spect,0.1
"midazolam - buccolam, 5 mg oral solution spray 1 ml",0.75
adverse effect: valproic acid,0.85
"electroencephalography on 8 or more leads with a minimum recording duration of 20 minutes, at the patient's bedside",0.85
"continuous electrocorticographic monitoring with video recording, per 24 hours",0.85
intraoperative electrocorticographic monitoring of spontaneous and/or evoked brain activity,0.85
"adverse effect: antiepileptics, others and unspecified",1.0
"cerebral cortical electrode removal, by craniotomy",0.75
epileptic back,0.9
ataxia,0.2
otorrhea,0.05
plica syndrome,0.0
eyekit,0.0
amblyopia,0.0
pyoderma,0.0
schizo research,0.0
myopia,0.0
nasal polyps,0.0
otalgia,0.05
castleman disease,0.0
symptom,0.1
presbyopia,0.0
cysteamine,0.05
labyrinthitis,0.05
xalatan,0.0
tongue depressor,0.0
temporary atrial capture,0.05
episiotomy,0.0
cardiac conduction disorders,0.05
alcoholic liver damage,0.05
psoriasis,0.0
kerasal,0.0
betahistine,0.05
neuroleptic threshold,0.1
hemarthrosis,0.0
eviplera,0.0
cannabis use disorder,0.1
oral wafer,0.1
diuresis,0.05
somatropin,0.05
fasciitis,0.0
jaw disease nos,0.0
bipolar disorders,0.05
nevirapine,0.1
hemoptysis,0.0
ibandronate,0.0
fragile x syndrome,0.1
hypertension,0.0
leukemia,0.0
eletriptan,0.05
vandetanib,0.0
monogenic obesity,0.0
corneal opacity,0.0
gating strategy,0.05
vitiligo,0.0
nystatin,0.0
tobacco use disorder,0.05
suicidal ideation,0.1
epidural,0.05
localization 1,0.2
abilify,0.25
sputum consistency,0.0
rapamycin,0.05
scopolamine,0.05
becaplermin,0.0
gingivitis,0.0
myringitis,0.0
psychoses,0.1
maprotiline,0.1
oxycontin,0.05
emphysema,0.0
pervasive developmental disorders,0.1
dna change,0.1
acne,0.0
cephalexin,0.0
modal progression,0.0
bumetanide,0.05
acitretin,0.0
valtrex,0.0
diarrhea,0.0
mupirocin,0.0
nesiritide,0.0
eplerenone,0.0
abatacept,0.0
uric acid,0.05
seizure,0.85
meningitis,0.1
endometriosis,0.0
tuberculosis,0.0
sarcoidosis,0.05
homocysteine,0.1
headache,0.2
benzodiazepines,0.75
measles,0.0
p53,0.0
cytomegalovirus,0.05
glomerulonephritis,0.0
vomiting,0.1
apnea,0.1
candidiasis,0.0
edema,0.1
gerd,0.0
radiotherapy,0.1
amphetamine,0.05
influenza,0.0
chemotherapy,0.0
warfarin,0.0
cyclosporine,0.05
osteomyelitis,0.0
pneumonia,0.0
aspirin,0.0
histidine csf,0.1
erythropoietin,0.0
intelligence,0.0
thalidomide,0.05
neurological,0.5
endocarditis,0.0
hiv rna,0.0
methotrexate,0.0
concussion,0.1
extubation,0.05
arsenic,0.0
minocycline,0.01
cardiomyopathy,0.0
leprosy,0.0
clopidogrel,0.0
unemployment,0.0
epinephrine,0.01
alopecia,0.0
oxaliplatin,0.0
mni,0.0
keratitis,0.0
hospice,0.05
gout,0.0
benzodiazepine back,0.75
osteoporosis,0.0
isoniazid,0.01
proline csf,0.1
antiplatelet,0.05
epileptic ids,1.0
ed,0.0
encephalopathy interpretation,0.25
ige,0.0
eag,0.1
seizure of assets,0.0
equipment,0.0
exam,0.0
neurological symptoms,0.25
conduct disorders,0.05
diagnosis,0.0
procedure,0.0
arg external,0.0
method,0.0
mental status,0.25
dissociative disorder,0.05
conclusion,0.0
biochemistry,0.0
state,0.0
ech treatment,0.1
suberate,0.0
disability examination,0.1
depression,0.2
treatment,0.25
nidus,0.1
error,0.0
myoclonic epilepsy,1.0
psychotropic,0.2
section,0.0
epidural check,0.05
cl elimination,0.0
acc conclusion,0.0
commands,0.0
exp decision,0.0
ekg,0.1
sample,0.0
device,0.1
detection,0.1
medication,0.5
object,0.0
emg,0.2
message,0.0
pathology,0.1
behavior,0.2
bio liquid electrical conclusion,0.0
technique,0.0
adnic,0.0
eastern information,0.0
learning disorder,0.1
Artifact,0.0
sample aspect,0.0
see below,0.0
specimen,0.0
analysis,0.0
restraints evaluated,0.1
ethyl chloride,0.05
class,0.0
environmental science analysis,0.0
acc research,0.0
aspect,0.0
na elimination,0.0
result,0.0
neuro symptoms,0.25
forms,0.0
context,0.0
research,0.0
communication,0.0
"headache, unspecified",0.1
"cerebral degeneration, unspecified",0.25
encephalopathy in diseases classified elsewhere,0.25
arrhythmia (cardiac) nos,0.05
abnormal movement,0.65
unspecified toxic encephalopathy,0.25
cardiac dysrhythmias,0.05
anxiety disorder,0.1
"acute, but ill-defined cerebrovascular disease",0.1
"infestation (lice, mites)",0.0
epilepsy gene panel,1.0
phobia,0.0
abnormal electrocardiogram [ecg] [ekg],0.1
grenoble,0.0
abnormal reflex,0.25
abnormal serum enzyme levels,0.1
eating disorder,0.0
spasm of muscle,0.2
esterases,0.0
neuropathies,0.25
parkinsonian syndromes,0.1
tics and choreas,0.2
rash and other nonspecific skin eruption,0.05
spontaneous movement,0.2
coagulation defects,0.05
muscle aches,0.05
red blood cell enzymopathies,0.0
substance addiction and disorders,0.1
"eosinophilia, unspecified",0.0
clinical data from external sources,0.0
cyclical vomiting syndrome unrelated to migraine,0.05
sps,0.0
"exposure to electric current, unspecified place",0.1
facial nerve disorders [cn7],0.05
=phenytoin,1.0
multiple sclerosis,0.05
neurofibromatosis,0.2
neurophysiology reports,0.65
jo-1 extractable nuclear ab,0.05
depakote,0.9
valproic acid concentration,0.85
fve title,0.0
=levetiracetam,1.0
easivent,0.0
c26 0,0.0
clinical info,0.0
gamma,0.0
pregabalin,0.85
glossodynia,0.05
s comment,0.85
title,0.0
clinical information,0.0
intellectual disability,0.2
p comment,0.0
family history of epilepsy and other diseases of the nervous system,0.85
epileptic back plate 2,0.85
"pulseless electrical activity, not elsewhere classified",0.05
cataplexy and narcolepsy,0.2
neuroleptic id.,0.1
neuroleptic id ur,0.1
electrocardiogram,0.05
myopathy,0.05
lyrica,0.85
defibrination syndrome,0.05
craniotomy with major device implant or acute complex cns principal diagnosis with mcc or chemotherapy implant or epilepsy with neurostimulator,1.0
preeclampsia and eclampsia,0.05
meniere's disease,0.05
piracetam,0.7
parkinson's disease,0.05
pyrazinamide,0.0
Stiripentol,1.0
1-hydroxymidazolam,0.1
Methsuximide,1.0
carbamazepine 200 mg oral tablet,0.85
oxcarbazepine 600 mg oral tablet,0.85
lacosamidedrip400mg(mk),0.85
cannabidiol,0.85
topiramate 25 mg oral tablet,0.85
gabapentin 50 mg/ml oral solution,0.85
gabapentin 400 mg oral capsule,0.75
gabapentin 100 mg oral capsule,0.75
phentermine / topiramate,0.75
gabapentin 300 mg oral capsule,0.85
amobarbital,0.25
dalfampridine,0.1
disorders of urea cycle metabolism,0.05
amifampridine,0.05
phenylketonuria [pku],0.05
other demyelinating diseases of central nervous system,0.1
phenobarbital free,0.25
jakob-creutzfeldt disease,0.05
"intracerebral electrode implantation for electroencephalographic recording, by stereotactic approach",0.85
intracerebral electrode removal,0.75
functional targeting of an intracerebral lesion by stereotactic means,0.25
paris cochinchina,0.0
cdkl5 gene,0.85
other radioisotope scan,0.1
adult intellectual efficiency evaluation test,0.1
dravet scn1a lille,1.0
lacosamidedrip200mg(mk),0.85
"underdosing of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter",1.0
phenytoin/dilantin dosage,0.85
phenobarbital dosage,0.85
phenobarbital liquid chromatography-mass spectrometry,0.75
"valproic acid, free and total",0.85
=phenytoin1000mg/100ml,0.85
lactoferrin,0.01
complement c3,0.05
Neisseria meningitidis DNA,0.05
citric acid,0.0
lidocaine0.25%/ns250mlnerveblock,0.05
formoterol / glycopyrronium,0.0
csf alpha-2 globulin,0.05
handgun assault - street or road,0.0
prot affepi included,0.85
"revision or change of component of cerebrospinal fluid shunt, via direct approach",0.1
accidental fall from other furniture,0.05
dna double strand igg,0.05
removal of maxillary and/or mandibular intraoral retention device,0.0
cholesterol/hdl ratio,0.0
"glucose 5% (g5), bag 250 ml",0.0
silver sulfadiazine,0.0
cd7+,0.0
symptom duration,0.1
contrast medium injection supplement for hip arthrography,0.0
"intraluminal dilation of a lower limb artery with intraluminal dilation of the common iliac artery and/or the homolateral external iliac artery with endoprosthesis placement, by transcutaneous arterial route",0.0
ipratropium_hfa_inhaler_12.9_gm_(procure_chg),0.0
hg tps 0,0.0
base deficit,0.05
vitamin d,0.05
oxygen content,0.05
o2 flow rate ir(t),0.0
cd19 absolute count,0.05
tb 1 antigen,0.0
lactate t4,0.05
"rozanolixizumab, 560 mg/4 ml inj",0.05
volume,0.0
encounter for screening for depression,0.05
azelastine,0.0
perflutren,0.0
"pulmonary bilobectomy with resection-anastomosis or bronchial reimplantation, by thoracotomy",0.0
apixaban ppp chro-mcnc,0.0
ssa60 titration,0.2
diclofenac,0.0
serum glucose,0.1
deprecated ck mb serpl eia-ccnc,0.0
prot d081fc j1 cx,0.0
other hepatobiliary or pancreas o.r. procedures with cc,0.0
ige allergen ovalbumin,0.0
hemodialysis,0.0
"reactions - complications, no accident mentioned - aspiration of a liquid",0.05
ceftazidime,0.0
cd63 secretion ratio,0.05
"contusion of bilateral front wall of thorax, initial encounter",0.0
mucoprotein/creatinine,0.05
anti-a,0.1
methadose,0.05
interstitial lung disease without cc/mcc,0.0
dystrophic epidermolysis bullosa,0.0
estazolam,0.2
"instrumental assessment of phonation with videoscopic and/or photographic recording, and stroboscopic examination of the larynx",0.05
low-density lipoprotein direct,0.0
Neutrophils/100 cells,0.0
"urinary catheterization as the cause of abnormal reaction of patient, or of later complication, without mention of misadventure at time of procedure",0.0
range of motion status,0.05
molecular class i typing,0.0
time 7,0.0
cpncustomsolution(chartwell),0.0
sex,0.0
occult blood screening test #3,0.0
"other congenital anomalies of lower limb, including pelvic girdle",0.0
viable cd34+ cells,0.0
human leukocyte antigen antibodies,0.05
"lacteol 340 mg, powder for oral suspension, sachet",0.0
vzv pcr/swab,0.05
tacrolimus 5 mg oral capsule,0.0
direct approach urethrolysis,0.0
urinary oxidant screening,0.05
acetaminophen-oxycodone,0.0
sars-cov-2 (covid-19) rna,0.0
"losartan 100 mg (arrow lab), tablets",0.0
tone and speech audiometry,0.05
study fk 506,0.0
metapneu/lba pcr,0.05
lancets.,0.0
latency,0.05
biological validation,0.0
total homovanillic acid 24 hour urine,0.1
urinary bilirubin concentration,0.01
fatty casts per low power field,0.0
excessive vomiting in pregnancy,0.0
"ligation, unilateral or bilateral section or resection of the vas deferens, by transcutaneous route",0.0
"pre-operative examination, unspecified",0.05
variant 2a,0.85
"incision of a ureterocele, by endoscopy",0.0
cytomegalovirus igm,0.05
hemoglobin a1b,0.0
2-Methyl-3-Hydroxybutyrate/Creatinine,0.05
"normal human immunoglobulins 4 g (gammanorm), injection solution, vial 24 ml",0.05
Streptococcus pneumoniae Danish serotype 22F IgG,0.0
Hepatitis B virus resistance panel,0.0
oxidants,0.05
anti-dq antibodies,0.05
dripdroporspacket,0.0
"multivitamins,_ther_oral_liq_120_ml",0.0
fentanyldrip2500mcg(mk),0.05
"miscellaneous cardiovascular devices associated with adverse incidents, not elsewhere classified",0.0
cmf diagnostic code,0.0
bap1 gene,0.1
cultural outing,0.0
time 1,0.0
greater than 5 white blood cell count per high power field (point of care),0.05
gp ia/iia (epitope 3) antibody (bkr),0.1
partial pressure of oxygen,0.05
other lytes battery,0.1
thyroid stimulating hormone inhibition test,0.05
urinalysis culture screen,0.05
alpha-2 globulin concentration,0.05
creatinine,0.05
lactate 5°c,0.0
symptoms of the muscles,0.1
c8 external,0.0
hsv pcr swab 3,0.0
dp inhibitor,0.1
nitroglycerin 0.3 mg sublingual tablet,0.0
emergency response unit,0.05
hemoglobin,0.05
b-type natriuretic peptide,0.0
"intraluminal dilation of a branch of the internal carotid artery with placement of an endoprosthesis, via transcutaneous arterial route",0.05
babesia microti dna,0.0
common ragweed (ambrosia elatior) ige,0.05
menatetrenone,0.05
16 g infiltration scale,0.0
cd4+,0.0
cd11c+,0.0
bilateral total ethmoidectomy by endoscopy,0.05
"skull flap craniotomy and transposition not involving the orbits, without posterior pole remodeling",0.1
impaired skin length #5,0.0
iabp volume,0.0
"transintestinal cutaneous ureterostomy with an undetubularized loop, by laparoscopy or retroperitoneoscopy",0.0
takayasu's disease,0.0
hemoglobin a1c,0.01
ruditapes spp ab.ige.rast class,0.0
blood glucose level at time 1,0.05
other and unspecified complications of birth; puerperium affecting management of mother,0.0
percutaneous antegrade ureteropyelography with ultrasound and/or radiologic guidance,0.0
"removal of a permanent intracavitary defibrillation lead and a permanent intracavitary cardiac pacing lead without the use of a specific device, via transcutaneous venous route",0.05
chloride,0.0
urine white blood cell count,0.05
methemoglobin,0.05
contact with plant thorns and sharp leaves - home,0.0
motorcyclist - collision with 2-3 wheel vehicle - traffic,0.0
dabigatran level,0.05
"occult blood, stool test #3",0.0
g8 paturin près,0.0
csf pneumococcal pcr,0.05
protein s actual/normal,0.0
percentage of hypersegmented neutrophils,0.0
other specified cough,0.0
lactobacillus acidophilus / lactobacillus sp,0.0
presence of unspecified artificial elbow joint,0.0
thoracoscopic surgical procedure converted to open procedure,0.0
arachidate (c20:0),0.0
"enoxaparin - clexane (= lovenox), 4,000 iu/0.4 ml, pre-filled syringe",0.0
pco2,0.05
Lymphocyte proliferation.pokeweed mitogen stimulation,0.05
decision analysis,0.0
"unifine pentips 8mm 1/2 """,0.0
reticulocytes,0.01
hx of ntd narr,0.05
rapid thromboelastography percentage lysis at 30 minute,0.0
citrateconc/1sgedta,0.0
"homolateral subclavian-axillary bypass, by direct approach",0.0
=lidocaine0.25%,0.0
yeast and hyphae count per high power field,0.0
ptyr240cys,0.0
capsaicin / lidocaine / menthol / methyl salicylate,0.0
trap 10 µm,0.0
melanocyte transfer autograft,0.0
insulin,0.0
proline sg,0.0
time 2,0.0
family history of malignant neoplasm of kidney,0.0
ristocetin 0.5,0.0
motorcyclist - collision with stationary object - traffic,0.0
"pedestrian on foot injured in collision with car, pick-up truck or van, unspecified whether traffic or nontraffic accident, initial encounter",0.0
long term (current) use of bisphosphonates,0.0
"pancreatin 12,500 u (eurobiol), enteric-coated capsule",0.0
addition of a ceramic-metal or mineral equivalent anchor pillar to a fixed plural dental prosthesis [bridge abutment],0.0
hybridization on metaphysical chromosomes (a probe),0.05
sodium,0.05
acetic acid / antipyrine / benzocaine / policosanol otic product,0.0
desoxycorticosterone,0.05
phenazopyridine,0.0
effects radiation nos,0.05
prostate specific ag free,0.0
platelet aggregation xxx induced,0.0
hospital preparation: dexamethasone 5mg capsule,0.1
anorectal endoscopic ultrasound with transanorectal guided biopsy,0.0
potassium chloride,0.05
deoxyhemoglobin,0.05
